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Spotty Calcification as a Marker of
Accelerated Progression of Coronary Atherosclerosis
Insights From Serial Intravascular Ultrasound
Yu Kataoka, MD, Kathy Wolski, MPH, Kiyoko Uno, MD, PHD, Rishi Puri, MBBS,
E. Murat Tuzcu, MD, Steven E. Nissen, MD, Stephen J. Nicholls, MBBS, PHD
Cleveland, Ohio
Objectives The purpose of this study was to determine atheroma progression in patients with spotty calcification.
Background Although extensively calcified atherosclerotic lesions have been proposed to be clinically quiescent, the presence of
spotty calcification within plaque has been reported to be associated with an increased incidence of ischemic cardio-
vascular events. The relationship between spotty calcification and disease progression has not been investigated.
Methods A total of 1,347 stable patients with angiographic coronary artery disease underwent serial evaluation of ather-
oma burden with intravascular ultrasound imaging. Patients with spotty calcification were identified based on
the presence of lesions (1 to 4 mm in length) containing an arc of calcification of 90°. Clinical characteristics
and disease progression were compared between patients with spotty calcification (n  922) and those with no
calcification (n  425).
Results Patients with spotty calcification were older (age 56 years vs. 54 years; p  0.001), more likely to be male (68%
vs. 54%; p  0.01), and have a history of diabetes mellitus (30% vs. 24%; p  0.01) and myocardial infarction
(28% vs. 20%; p  0.004), and have lower on-treatment high-density lipoprotein cholesterol levels (48  16
mg/dl vs. 51  17 mg/dl; p  0.001). Patients with spotty calcification demonstrated a greater percent ather-
oma volume (PAV) (36.0  7.6% vs. 29.0  8.5%; p  0.001) and total atheroma volume (174.6  71.9 mm3
vs. 133.9  64.9 mm3; p  0.001). On serial evaluation, spotty calcification was associated with greater pro-
gression of PAV (0.43  0.07% vs. 0.02  0.11%; p  0.002). Although intensive low-density lipoprotein
cholesterol and blood pressure lowering therapy slowed disease progression, these efficacies were attenuated in
patients with spotty calcification.
Conclusions The presence of spotty calcification is associated with more extensive and diffuse coronary atherosclerosis and
accelerated disease progression despite use of medical therapies. (J Am Coll Cardiol 2012;59:1592–7)
© 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.03.012Calcification is a common finding in coronary arteries and
has long been known to occur as a part of the atherosclerotic
process (1). Traditionally, calcified plaque has been consid-
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2012, accepted March 6, 2012.ered the established, stable, and quiescent atheroma. We
previously demonstrated that calcified plaques are less likely
to undergo changes in atheroma burden (2). In contrast, a
small amount of calcium in a spotty distribution was
reported as a characteristic of vulnerable plaque that con-
tributes to plaque instability (3). Recent studies using
intravascular ultrasound (IVUS) or multislice computed
tomography revealed that spotty calcification is more fre-
quently observed in the culprit lesions of patients with acute
coronary syndrome (4,5). Thus, this calcium pattern is an
important characteristic of vulnerable plaque leading to
plaque rupture. Recent evidence indicated that coronary
artery calcification can occur via a complex, regulated
process of biomineralization resembling osteogenesis (6–8).
As the subintimal lipid deposition, atherogenic, and inflam-
matory cytokines induce the osteogenic changes in the
arterial wall, which lead to the development of calcification,
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May 1, 2012:1592–7 Spotty Calcification and Disease Progressionthe presence of spotty calcification may influence not only
plaque vulnerability but also atheroma progression. How-
ever, the natural history of atheroma burden in the setting of
spotty calcified lesion remains to be fully characterized.
IVUS permits quantification of atheroma burden and im-
aging of coronary calcium with good histological correlation
(9). IVUS has also enhanced the understanding of the factors
hat influence atheroma progression and its response to
se of medical therapies (10–16). The present study
nvestigated the extent and serial change of coronary athero-
clerosis in patients with spotty calcification using antiathero-
clerotic pharmacological therapies.
ethods
tudy population. From the pooled data of 7 prospective
therosclerosis progression and/or regression IVUS trials,
ncluding 3,479 stable patients with established coronary
rtery disease (CAD), we selected 1,347 patients with spotty
alcification only or without any calcium. Spotty calcifica-
ion was defined as the presence of lesions 1 to 4 mm in
ength containing an arc of calcification of 90° (4). In the
resent analysis, we excluded patients who had extensive
alcification only with an arc of calcification of 90° (n 
38) and patients with both extensive and spotty calcifica-
ion (n  1,469). These 7 studies were the REVERSAL
Reversal of Atherosclerosis With Aggressive Lipid Low-
ring) study (10), the CAMELOT (Comparison of
mlodipine Versus Enalapril to Limit Occurrences of
hrombosis) study (11), the ACTIVATE (Acyl:
holesterol Acyltransferase Intravascular Atherosclerosis
reatment Evaluation) study (12), the ASTEROID (A
tudy to Evaluate the Effect of Rosuvastatin on Intra-
ascular Ultrasound-Derived Coronary Atheroma Bur-
en) trial (13), the ILLUSTRATE (Investigation of
ipid Level Management Using Coronary Ultrasound to
ssess Reduction of Atherosclerosis by Cholesteryl Ester
ransfer Protein Inhibition and High-Density Lipopro-
ein Elevation) study (14), the PERISCOPE (Efficacy
tudy of Pioglitazone Compared to Glimepiride on
oronary Atherosclerotic Disease Progression in Sub-
ects With Type 2 Diabetes Mellitus) trial (15), and the
TRADIVARIUS (Effect of Rimonabant on Progression
f Atherosclerosis in Patients With Abdominal Obesity
nd Coronary Artery Disease) study (16). All patients
ere required to have CAD, which was defined as having
t least 1 lumen narrowing 20% in a major epicardial
oronary artery on a diagnostic coronary angiogram
erformed for clinical indication. Each study was ap-
roved by the institutional review boards of the partici-
ating clinical trial sites, and all participants in the trials
rovided informed written consent before enrollment.
cquisition and analysis of IVUS images. The acquisi-
ion and analysis of ultrasonic images were previously
escribed in detail (10–16). In brief, after anticoagulation
herapy and administration of intracoronary nitroglycerin,n IVUS catheter (30 to 40
Hz) was inserted distally
ithin the coronary artery. The
arget vessel for imaging was re-
uired to have a segment of at
east 30 mm in length without
umen narrowing of 50%, a
istory of revascularization, and
as not considered to be the
ulprit vessel for a previous myo-
ardial infarction. Continuous
ltrasonic imaging was acquired
t a constant rate of 0.5 mm/s.
mages were digitized for analy-
is in a single core laboratory by
ersons who were blinded to the
linical characteristics and treat-
ent status of the patients. The
atching arterial segment was
efined from the images acquired at baseline and follow-up
tudies on the basis of the anatomic location of proximal and
istal side branches (fiduciary points). Images spaced pre-
isely 1 mm apart in the segment of interest were selected
or analysis.
The plaque area was defined as the difference in area
ccupied by the lumen and external elastic membrane
EEM) borders. The total atheroma volume (TAV) was
alculated by summation of the plaque area calculated for
ach measured image and subsequently normalized to ac-
ount for difference in segment length between subjects:
AVnormalized (mm
3)  [(EEMarea  LUMENarea)/
umber of slices in pullback]  median number of slices in
he study population.
The percent atheroma volume (PAV) was calculated as
he proportion of vessel wall volume occupied by atheroscle-
otic plaque: PAV (%)  [(EEMarea  LUMENarea)/
 EEMarea]  100.
Volumes occupied by the lumen and EEM were similarly
calculated by summation of their respective areas in each
measured image and subsequently normalized to account for
differences in segment length between subjects. The remod-
eling index at the most diseased site was calculated as the
ratio of the EEM area at the diseased site compared with
the least diseased site within the proximal 10 mm.
Statistical analysis. Continuous variables are expressed as
mean SD or median, and categorical variables as percent-
ages. The chi-square test was used to test for differences in
categorical variables between groups, and continuous data
were compared using unpaired t-tests, or Mann-Whitney
log rank tests when the variable was not normally distrib-
uted. Serial change from baseline in atheroma burden and
vessel dimensions was examined using analysis of covariance
(ANCOVA), with the baseline value as a covariate and
grouping variable (spotty calcium or no calcium) as a factor.
Characteristics at baseline with an imbalance between
Abbreviations
and Acronyms
ANCOVA  analysis of
covariance
CAD  coronary artery
disease
EEM  external elastic
membrane
HDL  high-density
lipoprotein
IVUS  intravascular
ultrasound
LDL  low-density
lipoprotein
PAV  percent atheroma
volume
TAV  total atheroma
volumegroups were also included in an ANCOVA model. Results

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Spotty Calcification and Disease Progression May 1, 2012:1592–7are expressed as least significant mean  SE. A p value
0.05 was considered significant. All statistical analyses
ere performed using SAS software, version 9.1.3 (SAS
nstitute, Cary, North Carolina).
esults
linical demographics in patients with spotty calcification.
potty calcification was observed in 922 patients (27%),
hereas 425 patients (12%) did not have any calcification
vident on imaging. Baseline clinical characteristics and the
se of antiatherosclerotic drugs are summarized in Table 1.
atients with spotty calcification were older, more likely to
e male, have a history of diabetes mellitus, and previous
yocardial infarction. These patients were also more likely
o be treated with statins at baseline, whereas other medi-
ation use was similar between the 2 groups. Patients with
potty calcification had lower total cholesterol and high-
ensity lipoprotein (HDL) cholesterol levels.
aseline atheroma burden and vessel dimensions. The
xtent of atheroma burden at baseline is summarized in
able 2. Patients with spotty calcification had more ather-
matous plaque, reflected by a higher PAV (36.0 7.6% vs.
9.0  8.5%; p  0.001), TAV (174.6  71.9 mm3 vs.
133.9  64.9 mm3; p  0.001), and percentage of images
that contained plaque (68.5% vs. 43.4%; p  0.001). The
remodeling ratio at the site that contained the greatest
Baseline Clinical CharacteristicsTable 1 Baseline Clinical Characteristics
No Calcium
(n  425)
Spotty
Calcium
(n  922) p Value
Age (yrs) 54 9 56 9 0.001
Caucasian (%) 87.3 90.6 0.07
Female (%) 45.9 31.6 0.001
BMI (kg/m2) 31.2 6.2 31.5 5.9 0.22
Hypertension (%) 74.8 77.2 0.33
Diabetes mellitus (%) 23.8 30.4 0.01
Hyperlipidemia (%) 73.9 76.4 0.32
Previous percutaneous coronary
intervention (%)
36.8 41.5 0.12
Previous myocardial infarction (%) 20.9 28.3 0.004
Current tobacco use (%) 20.5 21.1 0.78
Baseline medications
Statin use (%) 68.9 75.1 0.01
Beta-blocker use (%) 68.9 72.2 0.21
Aspirin use (%) 91.1 92.3 0.43
ACE inhibitor use (%) 42.8 47.3 0.12
Baseline biochemistry data
Total cholesterol (mg/dl) 184 45 177 43 0.01
LDL cholesterol (mg/dl) 107 37 103 35 0.08
HDL cholesterol (mg/dl) 45 13 42 11 0.001
Triglyceride (mg/dl) 142 (95–207) 140 (101–200) 0.96
hsCRP (mg/l) 2.4 (1.1–6.1) 2.9 (1.3–5.9) 0.41
Systolic blood pressure (mm Hg) 126 15 126 15 0.51
Diastolic blood pressure (mm Hg) 76 9 75 9 0.29
Values are mean  SD, %, or median (interquartile range).
ACE angiotensin-converting enzyme; BMI body mass index; HDL high density lipoprotein;
sCRP  high sensitivity C-reactive protein; LDL  low density lipoprotein.amount of plaque was similar between the 2 groups. Vessel
wall dimensions are summarized in Table 2. Patients with
spotty calcification had larger vessels, demonstrated by a
larger EEM (483.8  167.1 mm3 vs. 455.8  156.1 mm3;
 0.004), but smaller lumen volume (309.2  112.9 mm3
vs. 321.9  112.8 mm3; p  0.04), consistent with more
extensive atherosclerosis.
Risk factor control. The use of antiatherosclerotic drugs
and the degree of risk factor control at follow-up are
summarized in Table 3. Beta-blockers were more likely to
be used in patients with spotty calcification, although this
difference failed to meet statistical significance. On therapy,
patients with spotty calcification had significantly lower
total cholesterol and HDL cholesterol levels. The groups
did not differ with regard to the degree of other risk factor
controls.
Serial change in plaque progression. The relationship
between spotty calcification and plaque progression is sum-
marized in Table 4. After controlling for baseline atheroma
burden, patients with spotty calcification exhibited greater
atheroma progression than patients without calcification,
Baseline Atheroma BurdenTable 2 Baseline Atheroma Burden
No Calcium
(n  425)
Spotty Calcium
(n  922) p Value
Percent atheroma volume (%) 29.0 8.5 36.0 7.5 0.001
Total atheroma volume (mm3) 133.9 64.8 174.6 71.9 0.001
Lumen volume (mm3) 321.9 112.7 309.2 112.9 0.04
EEM volume (mm3) 455.8 156.0 483.8 167.1 0.004
Percentage of images
containing plaque (%)
43.4 68.5 0.001
Remodeling ratio 0.966 0.202 0.948 0.195 0.19
Constrictive (%) 45.7 49.2
No remodeling (%) 28.2 25
Expansive (%) 26.1 25.9
Values are mean  SD or %.
EEM  external elastic membrane.
On-Treatment Medications and Risk Factor ControlTable 3 On-Treatment Medications and Risk Factor Control
No Calcium
(n  425)
Spotty
Calcium
(n  922) p Value
Concomitant medications
Statin use (%) 95.5 94.3 0.33
Beta-blocker use (%) 69.2 73.6 0.08
Aspirin use (%) 91.3 93.6 0.12
ACE inhibitor use (%) 50.1 53.4 0.26
On-treatment biochemistry data
Total cholesterol (mg/dl) 169 33 164 31 0.01
LDL cholesterol (mg/dl) 87 27 87 25 0.85
HDL cholesterol (mg/dl) 51 17 47 15 0.001
Triglyceride (mg/dl) 129 (94–192) 131 (95–177) 0.83
CRP (mg/dl) 2.1 (1.0–5.0) 2.1 (1.0–5.0) 0.76
Systolic blood pressure (mm Hg) 127 12 127 12 0.83
Diastolic blood pressure (mm Hg) 76 7 76 7 0.59Values are %, mean  SD, or median (interquartile range).
Abbreviations as in Table 1.
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May 1, 2012:1592–7 Spotty Calcification and Disease Progressiondemonstrated by a greater change in PAV (0.43 0.07% vs.
0.02  0.11%; p  0.002). Furthermore, an ANCOVA
model, including terms for baseline PAV, age, gender,
diabetes mellitus, baseline low-density lipoprotein (LDL)
cholesterol and HDL cholesterol levels, and baseline statin
use, did not change the results, reflected by still greater
progression of PAV in patients with spotty calcification
(change in PAV: 0.68  0.12% vs. 0.05  0.17%; p 
0.002) (Table 4). No difference was observed with regard to
changes in TAV (0.77  0.42 mm3 vs. 1.56  0.62
m3; p  0.29), EEM (6.73  0.87 mm3 vs.  6.90 
1.28 mm3; p  0.911), and lumen volume (5.89  0.71
mm3 vs. 5.49  1.05 mm3; p  0.76). The remodeling
ndex at follow-up was lower in patients with spotty
alcification (0.92  0.19 vs. 0.95  0.20; p  0.02). This
was consistent with the finding that patients with spotty
calcification were more likely to show constrictive remod-
eling (55.1% vs. 49.5%; p  0.04). Assigned treatment and
measures of atheroma burden in each of the IVUS clinical
trials are summarized in Table 5. There were no significant
differences in assigned medical therapies of each trial be-
tween patients with and without spotty calcification. Pa-
tients with spotty calcification in each trial consistently
exhibited a higher baseline PAV. In addition, a similar
trend with greater progression of PAV was observed in
these patients (Table 5).
The impact of intensive LDL cholesterol and blood
pressure lowering therapy on coronary atherosclerosis was
also investigated (Fig. 1). Intensive lowering of LDL
cholesterol to 70 mg/dl had a beneficial impact on
progression of PAV in both patients with spotty calcifica-
tion (0.05  0.13% vs. 0.57  0.08%; p  0.03) and
atients without calcification ( 0.49  0.20% vs. 0.23 
.12%; p  0.01) (Fig. 1, left panel). However, patients
ithout calcification were more likely to slow disease pro-
Serial Change in AtheromaBu den and Vessel R modelingTable 4 S rial Change in AtheromaBurden and Vessel Remodeling
No Calcium
(n  425)
Spotty
Calcium
(n  922) p Value
Percent atheroma volume (%)* 0.02 0.10 0.43 0.07 0.002
Adjusted percent atheroma
volume (%)†
0.05 0.17 0.68 0.12 0.002
Total atheroma volume (mm3)* 1.56 0.62 0.77 0.42 0.29
Lumen volume (mm3) 5.49 1.05 5.89 0.71 0.75
EEM volume (mm3) 6.90 1.28 6.73 0.87 0.91
Remodeling index 0.95 0.21 0.93 0.19 0.01
Constrictive (%) 49.5 55.1
No remodeling (%) 23.9 24.2
Expansive (%) 26.5 20.7
Mean follow-up duration (days) 656.8 105.1 648.8 107.9 0.21
Values are mean  SD or %. *After adjusted for baseline atheroma burden. †After adjusted for
differences in clinical characteristics including age, gender, diabetes, baseline low-density lipopro-
tein cholesterol and high-density lipoprotein cholesterol levels, statin use and baseline atheroma
burden.
EEM  external elastic membrane.ression than patients with spotty calcification. With regardo achieving a systolic blood pressure level 130 mm Hg, a
imilar trend was observed in change in PAV at follow-up
Fig. 1, right panel).
iscussion
he present study shows that spotty calcification is related
o a presence of greater atheromatous plaque and more
isease progression. Although intensive control of LDL
holesterol and blood pressure slow plaque progression, this
enefit was attenuated in patients with spotty calcification.
Assigned Therapy and Measures oftheroma Burden in Each Clinical TrialTable 5 Assigned Th rapy and Measures ofAtheroma Burden in Each Clinical Trial
No Calcium
(n  425)
Spotty Calcium
(n  922) p Value
REVERSAL (n  232) 0.33
40 mg pravastatin, n (%) 55/119 (46.2) 64/119 (53.8)
80 mg pravastatin, n (%) 45/113 (39.8) 68/113 (60.2)
Baseline PAV (%) 30.2 11.1 36.2 9.3 0.001
Change in PAV (%) 1.11 0.35 1.86 0.31 0.11
CAMELOT (n  116) 0.64
Placebo, n (%) 9/34 (26.5) 25/34 (73.5)
Amlodipine, n (%) 14/44 (31.8) 30/44 (68.2)
Enalapril, n (%) 14/38 (36.8) 24/38 (63.2)
Baseline PAV (%) 30.7 9.9 39.3 7.5 0.001
Change in PAV (%) 0.01 0.58 1.35 0.40 0.05
ACTIVATE (n  156) 0.13
Placebo, n (%) 23/84 (27.4) 61/84 (72.6)
Pactimibe, n (%) 28/72 (38.9) 44/72 (61.1)
Baseline PAV (%) 29.2 7.9 36.7 7.7 0.001
Change in PAV (%) 0.04 0.49 1.39 0.35 0.02
ASTEROID (n122) 0.08
40 mg rosuvastatin, n (%) 34/122 (27.9) 88/122 (72.1)
Baseline PAV (%) 28.8 6.7 36.6 7.0 0.001
Change in PAV (%) 1.81 0.61 0.67 0.38 0.11
ILLUSTRATE (n  364) 0.95
Atorvastatin, n (%) 60/174 (34.5) 114/174 (65.5)
Torcetrapib/atrovastatin, n (%) 65/190 (34.2) 125/190 (65.8)
Baseline PAV (%) 27.5 6.0 34.9 7.1 0.001
Change in PAV (%) 0.72 0.32 0.13 0.23 0.03
PERISCOPE (n  127) 0.44
Glimepiride, n (%) 14/67 (20.9) 53/67 (79.1)
Pioglitazone, n (%) 16/60 (26.7) 44/60 (73.3)
Baseline PAV (%) 31.7 9.2 37.5 7.0 0.004
Change in PAV (%) 0.57 0.64 1.11 0.36 0.47
STRADIVARIUS (n  230) 0.89
Placebo, n (%) 24/113 (21.2) 89/113 (78.8)
20 mg rimonabant, n (%) 24/117 (20.5) 93/117 (79.5)
Baseline PAV (%) 27.4 6.0 34.2 6.5 0.001
Change in PAV (%) 0.02 0.51 0.39 0.26 0.48
Values are n/N (%) or mean  SD.
ACTIVATE  ACAT Intravascular Atherosclerosis Treatment Evaluation; ASTEROID  A Study to
Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma
Burden; CAMELOT  Comparison of Amlodipine Versus Enalapril to Limit Occurrences of Throm-
bosis; ILLUSTRATE A30:A47 Investigation of Lipid level Management Using Coronary Ultrasound
to Assess Reducation of Atherosclerosis by CETP inhibition and HDL Elevation; PAV  percent
atheroma volume; PERISCOPE  Efficacy Study of Pioglitazone Compared to Glimepiride on
Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus;
REVERSAL  Reversal of Atherosclerosis With Aggressive Lipid Lowering; STRADIVARIUS 
Strategy to Reduce Atherosclerosis Development Involving Administrationof Rimonabant-The
Intravascular Ultrasound Study.
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Spotty Calcification and Disease Progression May 1, 2012:1592–7Our findings highlight the need of stricter risk factor control
for the prevention of disease progression in these patients.
Considerable interest has focused on composition and
morphological characteristics of individual atherosclerotic
plaques, which are proposed to be related to plaque vulner-
ability. In postmortem studies, plaque ruptures and thin-
capped atheromas, considered to represent vulnerable
plaques, contain small calcium deposits (17,18). Recent
studies also demonstrated that spotty calcification was
frequently observed in the culprit atherosclerotic lesions
associated with acute coronary syndrome (4,5). Thus, evi-
dence has been accumulating that spotty calcification is
closely related to vulnerable plaque. However, this calcium
pattern has been evaluated only after the occurrence of acute
coronary events in these studies, and it remains to be
determined whether they are prevalent and how disease
behaves in spotty calcified atheromas at nonculprit lesions in
stable patients. The present analysis demonstrated that
spotty calcification was observed in 27% of stable patients,
and these lesions had larger atheromatous plaque volume
with greater disease progression despite use of antiathero-
sclerotic medical therapies.
The finding that the presence of calcium is associated
with greater atheroma burden is consistent with previous
reports of a correlation between the amount of plaque and
calcium in pathological studies and in small cohort studies
by IVUS (19,20). Although calcified atherosclerotic lesions
have been viewed conventionally as an advanced, stable, and
quiet atherosclerotic form, spotty calcified lesions identify
patients with more extensive and diffuse plaque. Plaque
calcification represents a dynamic process that is related to
Figure 1 Intensive Risk Factor Modification and Plaque Progre
Changes in percent atheroma volume (PAV) in patients with spotty calcification an
low-density lipoprotein cholesterol (LDL-C) (left panel) and systolic blood pressureoxidized lipids and inflammatory activity (6–8). At early- dtage atherosclerosis, oxidized lipids, lipoproteins, and var-
ous inflammatory cytokines elaborated during atherogene-
is stimulate the expression and activity of osteoblast-like
ells within the arterial wall, resulting in the development of
alcium deposit (6–8). Some in vitro and in vivo studies
eported that macrophage and tumor necrosis factor-alpha
receded osteogenic activity and promoted plaque calcifica-
ion (21,22). Considering that the process of plaque calci-
cation is triggered by lipid oxidation and inflammatory
esponse, spotty calcified plaque may contain more lipid and
nflammatory materials than noncalcified lesions, and there-
ore, is likely to undergo greater atheroma progression. This
alcium pattern does not seem to be degenerative, but
eflects an active state that has extensive plaque volume and
ccelerated progression.
In the present study, constrictive remodeling was more
ommonly observed in patients with spotty calcification.
he development of calcification has been considered an
steogenic process associated with inflammatory reactions
21,22). Therefore, this process may induce osteogenic
ifferentiation and mineralization of vascular smooth mus-
le cell, resulting in the impaired vascular remodeling.
The benefits of LDL cholesterol and blood pressure
owering therapies on atheroma progression were dimin-
shed in patients with spotty calcification. Because calcium
eposits are heavily infiltrated by macrophages, oxidized
ipids, and inflammatory cytokines (21,22), stricter risk
ontrol may be needed for the prevention of disease pro-
ression in these patients. Our results have potential impli-
ations for the prediction of which patients are likely to
ut calcification stratified according to degree of
(right panel) control.ssion
d witho
(SBP)erive benefit from aggressive risk factor intervention.
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May 1, 2012:1592–7 Spotty Calcification and Disease ProgressionStudy limitations. A number of caveats should be noted.
his is an analysis of pooled data from 7 clinical IVUS trials
o monitor atheroma progression. However, all images were
nalyzed in the same core laboratory using well-validated
nd standardized techniques. The ability to pool data from
number of clinical trials provided a database of a large
umber of patients with serial IVUS evaluation of plaque
burden. Although our analysis reflects the relationship between
spotty calcification and disease progression in patients with
CAD, the resultant impact on clinical outcome remains to be
determined. IVUS is limited in its ability to characterize plaque
composition. Therefore, the plaque composition of spotty
calcified lesions and its modification under medical therapies
require further characterization.
Conclusions
In summary, spotty calcification is an important pattern
identifying patients with diffuse, extensive atherosclerosis
and accelerated disease progression. Although intensive risk
factor control therapies are effective to slow plaque progres-
sion, these efficacies were attenuated in patients with spotty
calcification. Our findings underscore stricter global risk
control for the prevention of plaque progression in these
patients.
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